Business Wire

TikkunLev Therapeutics Emerges from Stealth Mode to Develop First-in-Class Precision Therapies for Heart Failure Targeting the Causal Disease Biology of Failing Heart Muscle

SALT LAKE CITY & SAN FRANCISCO--(BUSINESS WIRE)--TikkunLev Therapeutics, a biotechnology company developing precision therapies targeting the causal disease biology of failing heart muscle, today ...
Business Wire

TikkunLev Therapeutics Announces the Publication of a Seminal Study in Nature Regenerative Medicine, Demonstrating the Potential Best-in-Class Profile of its cBIN1 Precision ...

SALT LAKE CITY & SAN FRANCISCO--(BUSINESS WIRE)--TikkunLev Therapeutics, a biotechnology company developing precision therapies targeting the causal disease biology of failing heart muscle, today ...